Talphera to Announce Q1 2024 Financial Results on May 14, 2024

SAN MATEO, Calif., May 2, 2024 -- Talphera, Inc. (Nasdaq: TLPH), a specialty pharmaceutical firm dedicated to developing and commercializing innovative therapies for medically supervised environments, has announced plans to release its first-quarter 2024 financial results after the market closes on Tuesday, May 14, 2024. Following the release, the company will host a live webcast and conference call at 4:30 p.m. Eastern Daylight Time/1:30 p.m. Pacific Daylight Time to discuss the financial outcomes and provide updates on its business activities.

The webcast, which will include a slide presentation, can be accessed through the Investors section of Talphera's website under the News & Events and Upcoming Events sections. A replay of the webcast will be available on the Talphera website for 90 days after the event.

Investors interested in participating in the conference call can dial 1-800-836-8184 for North American callers or 1-646-357-8785 for international callers outside of Canada. The conference ID for the call is 79169.

Talphera, Inc. is a pharmaceutical company that specializes in creating and bringing to market innovative therapies designed for use in medically supervised settings. Their leading product candidate, Niyad™, a lyophilized formulation of nafamostat, is currently being evaluated under an investigational device exemption (IDE) as an anticoagulant for the extracorporeal circuit. Niyad™ has also received Breakthrough Device Designation status from the FDA, highlighting its potential to address unmet medical needs.

Additionally, Talphera is developing two pre-filled syringes that it has in-licensed from its partner Aguettant. The first, Fedsyra™, is a pre-filled ephedrine syringe, and the second, PFS-02, is a pre-filled phenylephrine syringe. These products are designed to enhance the safety and efficiency of drug administration in clinical settings.

Talphera continues to focus on expanding its portfolio of specialized therapies, aiming to meet critical needs in healthcare through innovation and strategic partnerships. The forthcoming financial results and business updates are expected to provide insights into the company's progress and future direction.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!